Terry Smith
Fundsmith
Terry Smith Catalyst Pharmaceuticals Inc stake
total: 91
Fundsmith CPRX trades
- Total transactions:
- 5
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 1
- Held since:
- 2025 Q1
- Held for:
- 5 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Terry Smith doesn't hold any Catalyst Pharmaceuticals Inc (CPRX) shares. To date, the estimated cost basis is nearly $22.94 for "buy" trades and estimated average "sell" price is $24.76. Fundsmith first purchased CPRX in 2025 Q1, initially acquiring about 2.15M shares. Since the initial investment in Catalyst Pharmaceuticals Inc (CPRX), Fundsmith has made 4 more transactions.
When did Terry Smith sell Catalyst Pharmaceuticals Inc (CPRX)?
Terry Smith sold off the entire Catalyst Pharmaceuticals Inc (CPRX) position in 2026 Q2.
When did Terry Smith buy Catalyst Pharmaceuticals Inc (CPRX)?
Terry Smith first invested in Catalyst Pharmaceuticals Inc (CPRX) in 2025 Q1 at the reported quarter-end price of $24.25 per share.
What's the cost basis of Fundsmith's CPRX stake?
The estimated cost basis for Catalyst Pharmaceuticals Inc (CPRX) stake is around $22.94 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $22.94
- Weighted AVG sell price:
- $24.76
Terry Smith's historical trades in Catalyst Pharmaceuticals Inc
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
0
|
$24.76
|
|
-100% (-844,887)
|
-0.16%
|
|
2026 Q1
|
0.16%
|
844,887
|
$24.76
|
$20,919,402
|
-74.88% (-2,518,920)
|
-0.36%
|
|
2025 Q3
|
0.33%
|
3,363,807
|
$19.70
|
$66,266,998
|
+24.17% (+654,721)
|
+0.07%
|
|
2025 Q2
|
0.26%
|
2,709,086
|
$21.70
|
$58,787,166
|
+25.93% (+557,812)
|
+0.05%
|
|
2025 Q1
|
0.24%
|
2,151,274
|
$24.25
|
$52,168,395
|
new
|
+0.24%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.